693.932 PEOPLE
| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Mata, F. Javier De La
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (10/10 displayed)
- 2023Removing lead from water with carboxylate dendrimers and magnetic nanoparticles modified with carboxylate dendrimerscitations
- 2023Ruthenium metallodendrimer against triple-negative breast cancer in micecitations
- 2023Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Modelscitations
- 2023Lipid-coated ruthenium dendrimer conjugated with doxorubicin in anti-cancer drug delivery: Introducing protocolscitations
- 2023Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary studycitations
- 2021Organometallic dendrimers based on Ruthenium(II) N-heterocyclic carbenes and their implication as delivery systems of anticancer small interfering RNAcitations
- 2020Fine-Tuning the Interaction and Therapeutic Effect of Cu(II) Carbosilane Metallodendrimers in Cancer Cells: An In Vitro Electron Paramagnetic Resonance Studycitations
- 2014Synthesis of new amphiphilic water‐stable hyperbranched polycarbosilane polymerscitations
- 2013Characterization of Dendrimers and Their Interactions with Biomolecules for Medical use by Means of Electron Magnetic Resonancecitations
- 2004Tris(pyrazolyl)borate carbosilane dendrimers and metallodendrimerscitations
Places of action
| Organizations | Location | People |
|---|
article
Ruthenium metallodendrimer against triple-negative breast cancer in mice
Abstract
Carbosilane metallodendrimers, based on the arene Ru(II) complex (CRD13) and integrated to imino-pyridinesurface groups have been investigated as an anticancer agent in a mouse model with triple-negative breastcancer. The dendrimer entered into the cells efficiently, and exhibited selective toxicity for 4T1 cells. In vivoinvestigations proved that a local injection of CRD13 caused a reduction of tumour mass and was non-toxic. ICPanalyses indicated that Ru(II) accumulated in all tested tissues with a greater content detected in the tumour.